Damora Therapeutics, Inc. (DMRA)
NASDAQ
20.67
+1.40 (+7.27%)
Closed
Oct 20, 2026
Day's Range
19.3020.92
52 wk Range
4.9538.33
Financial Statements - DMRA - Damora Therapeutics, Inc.
Revenue
0
Net Income
-209.83M▼ 878.8%
EBITDA
-210.75M▼ 945.4%
Free Cash Flow
-6.72M▲ 63.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 0 | 0 |
| Cost of Goods | - | - |
| Gross Profit | - | - |
 Operating Expense | - | - |
| Operating Income | -210.87M | -21.29M |
| Non-Operating Interest | - | - |
| Other Income Expense | -84K | -950K |
| Pre Tax Income | -209.78M | -21.39M |
| Income Tax | 50K | 41K |
| Net Income | -209.83M | -21.43M |
| EPS Basic | -3.98 | -18.53 |
| EPS Diluted | -3.98 | -18.53 |
| Basic Shares Outstanding | 1.36M | 1.15M |
| Diluted Shares Outstanding | 1.36M | 1.15M |
| Ebit | -210.87M | -21.29M |
| Ebitda | -210.75M | -20.16M |
| Net Income Continuous Operations | -209.83M | -21.43M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
